Trials / Completed
CompletedNCT00548509
The Effect of Vitamin K2 on Bone Turnover
Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- Eisai Limited · Industry
- Sex
- Female
- Age
- 49 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the effect of menatetrenone on bone turnover in postmenopausal patients with osteoporosis. One month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin. Moderate increases of bone resorption and formation markers were observed after 6 months. These changes may contribute to fracture prevention in patients with osteoporosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Menatetrenone (Vitamin K2) |
Timeline
- Start date
- 2002-02-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2007-10-24
- Last updated
- 2018-10-29
Locations
4 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00548509. Inclusion in this directory is not an endorsement.